Cargando…
P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171475/ http://dx.doi.org/10.1097/01.HS9.0000936344.05666.80 |
| _version_ | 1785039424546930688 |
|---|---|
| author | Spiliopoulou, V. Ntanasis-Stathopoulos, I. Malandrakis, P. Gavriatopoulou, M. Theodorakakou, F. Fotiou, D. Syrigou, R. E. Migkou, M. Roussou, M. Eleutherakis-Papaiakovou, E. Kastritis, E. Dimopoulos, M. A Terpos, E. |
| author_facet | Spiliopoulou, V. Ntanasis-Stathopoulos, I. Malandrakis, P. Gavriatopoulou, M. Theodorakakou, F. Fotiou, D. Syrigou, R. E. Migkou, M. Roussou, M. Eleutherakis-Papaiakovou, E. Kastritis, E. Dimopoulos, M. A Terpos, E. |
| author_sort | Spiliopoulou, V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171475 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101714752023-05-11 P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY Spiliopoulou, V. Ntanasis-Stathopoulos, I. Malandrakis, P. Gavriatopoulou, M. Theodorakakou, F. Fotiou, D. Syrigou, R. E. Migkou, M. Roussou, M. Eleutherakis-Papaiakovou, E. Kastritis, E. Dimopoulos, M. A Terpos, E. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171475/ http://dx.doi.org/10.1097/01.HS9.0000936344.05666.80 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Spiliopoulou, V. Ntanasis-Stathopoulos, I. Malandrakis, P. Gavriatopoulou, M. Theodorakakou, F. Fotiou, D. Syrigou, R. E. Migkou, M. Roussou, M. Eleutherakis-Papaiakovou, E. Kastritis, E. Dimopoulos, M. A Terpos, E. P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title | P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title_full | P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title_fullStr | P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title_full_unstemmed | P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title_short | P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY |
| title_sort | p54 oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and covid-19; a single-center, prospective study |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171475/ http://dx.doi.org/10.1097/01.HS9.0000936344.05666.80 |
| work_keys_str_mv | AT spiliopoulouv p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT ntanasisstathopoulosi p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT malandrakisp p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT gavriatopouloum p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT theodorakakouf p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT fotioud p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT syrigoure p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT migkoum p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT roussoum p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT eleutherakispapaiakovoue p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT kastritise p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT dimopoulosma p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy AT terpose p54oralantiviralsritonavirnirmatrelvirandmolnupiravirarehighlyeffectiveinpatientswithmultiplemyelomaandcovid19asinglecenterprospectivestudy |